GENEURO SA (GNRO.PA) Stock Price & Overview
EPA:GNRO • CH0308403085
Current stock price
The current stock price of GNRO.PA is 0.0308 EUR. Today GNRO.PA is down by -0.65%. In the past month the price increased by 2.67%. In the past year, price decreased by -81.05%.
GNRO.PA Key Statistics
- Market Cap
- 916.608K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
GNRO.PA Stock Performance
GNRO.PA Stock Chart
GNRO.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GNRO.PA. When comparing the yearly performance of all stocks, GNRO.PA is a bad performer in the overall market: 97.34% of all stocks are doing better.
GNRO.PA Earnings
GNRO.PA Forecast & Estimates
GNRO.PA Groups
Sector & Classification
GNRO.PA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GNRO.PA Ownership
GNRO.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.74 | 38.133B | ||
| ARGX | ARGENX SE | 24.79 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 19.212B | ||
| ABVX | ABIVAX SA | N/A | 8.666B | ||
| 2X1 | ABIVAX SA | N/A | 8.635B | ||
| GLPG | GALAPAGOS NV | N/A | 1.904B | ||
| GXE | GALAPAGOS NV | N/A | 1.877B | ||
| NANO | NANOBIOTIX | N/A | 1.362B | ||
| IVA | INVENTIVA SA | N/A | 1.09B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| PHIL | PHILOGEN SPA | 18.17 | 666.672M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 862.75 | 438.775M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About GNRO.PA
Company Profile
GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Company Info
IPO: 2016-04-15
GENEURO SA
3, Chemin du Pre-Fleuri
Plan-les-Ouates GENEVE CH
Employees: 17
Phone: 41225524800
GENEURO SA / GNRO.PA FAQ
What does GNRO do?
GeNeuro SA is a clinical stage company, which engages in the research and development of pharmaceutical products. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 19 full-time employees. The company went IPO on 2016-04-15. The firm's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The firm's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
What is the current price of GNRO stock?
The current stock price of GNRO.PA is 0.0308 EUR. The price decreased by -0.65% in the last trading session.
Does GENEURO SA pay dividends?
GNRO.PA does not pay a dividend.
What is the ChartMill rating of GENEURO SA stock?
GNRO.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What sector and industry does GENEURO SA belong to?
GENEURO SA (GNRO.PA) operates in the Health Care sector and the Biotechnology industry.
Who owns GENEURO SA?
You can find the ownership structure of GENEURO SA (GNRO.PA) on the Ownership tab.